Brought to you by 
Novartis out-licenses encorafenib to Array to make way for GSK oncology deal
22 Sep 2017
Executive Summary
In order to satisfy conditions to close its acquisition of GlaxoSmithKline's oncology business (announced in April 2014), Novartis Pharma AG licensed Array BioPharma Inc. exclusive worldwide rights to develop, manufacture, and sell its Phase III BRAF inhibitor encorafenib (LGX818; NVPLGX818) for melanoma. Encorafenib is also in Phase I/II for colorectal cancer. Novartis will assign or license to Array patent and IP rights covering the compound, plus regulatory filings, technology, inventory, a companion diagnostic agreement (while not specified, this could be the November 2014 deal with Qiagen), and other contract rights.
Deal Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Alliance
- Product or Technology Swap
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis out-licenses encorafenib to Array to make way for GSK oncology deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice